INCY INCYTE CORP Insider Trading

CMO Steven Stein sold 28,237 shares of INCY at $113.05 under 10b5-1 plan; holds 22,995 shares post-sale.

Steven H Stein, CMO & Head of Late-Stage Development, sold 28,237 shares at $113.05 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings by 55.1% from 51,232 shares to 22,995 shares and realizing $3,192,192.85 in proceeds. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it does not reflect current decision-making or conviction about the stock's prospects. Incyte fundamentals remain solid with revenue of $1,272,676,000.00 in the latest quarter, net income of $303,330,000.00, annual revenue growth of +21.2%, and a P/E of 16.27, suggesting no material deterioration in business quality warranting urgent investor attention. The stock is trading 2.0% below its 52-week high of $118.97 and has appreciated 16.9% over the past 30 days and 19.2% over 90 days, reflecting recent positive momentum independent of this scheduled sale.

Director Paul J Clancy sold 15,000 shares of INCY at $94.93 ($1.4M) via pre-arranged 10b5-1 plan

Paul J Clancy, a Director at Incyte, sold 15,000 shares at $94.93 for a total value of $1,423,950.00, reducing his holdings from 38,741 shares to 23,741 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Incyte's latest quarter shows revenue of $1,272,676,000.00 and net income of $303,330,000.00, with annual revenue growth of +21.2%, reflecting solid operational performance. Since the sale was part of a scheduled trading plan rather than a discretionary decision, it does not carry signal about current market timing or confidence levels.

INCY President R&D sells 18,667 shares at $96.50; retains 262,692 shares; stock down 13.0% from 52-week high, up 6.0% in 30 days

CAGNONI PABLO J, President and Global Head of R&D, sold 18,667 shares of INCYTE CORP at $96.50, reducing holdings to 262,692 shares and maintaining a substantial position. The sale occurred as the stock trades 13.0% below its 52-week high of $110.57 despite a recent 6.0% 30-day gain, suggesting the sale was executed during a partial recovery from recent weakness. His prior two sales at INCY—on 2026-03-17 and 2026-02-19—resulted in mixed near-term price action (up 1.2% and down 10.0% respectively over the following 30 days), with no measurable 90-day outcomes yet, offering limited insight into his timing acuity at this ticker. The company exhibits solid fundamentals with $1.4B quarterly revenue, a 21.2% annual growth rate, and a low 7.84 P/E ratio, providing no obvious operational distress signal.

INCY President Pablo Cagnoni sells 18.7K shares ($1.8M) at $94.24; retains 234.8K shares post-transaction

Pablo Cagnoni, President of R&D at Incyte, sold 18,667 shares at $94.24 on 2026-03-17 for $1,759,178.08, reducing his holdings by 7.4% to 234.8K shares. The sale occurred as INCY stock has declined 8.1% over the past 30 days and 9.5% over 90 days, trading 15.9% below its 52-week high of $110.57. Cagnoni's cross-ticker track record shows only 1 prior open-market sell, and his only prior trade at INCY occurred on 2026-02-19 (a sell whose timing outcome is not yet measurable). The company's fundamentals remain solid with $1.4B in latest-quarter revenue, $424.2M net income, and 21.2% annual revenue growth, though the stock's recent price weakness and the insider's continued substantial holdings suggest no imminent distress signal.

INCY President of R&D sells 18,668 shares at $100.91; retains 234,800 shares after 7.4% reduction

Pablo J. Cagnoni, President of R&D at Incyte, sold 18,668 shares on 2026-02-19 at $100.91, reducing holdings from 253,468 to 234,800 shares. The sale occurred near the 52-week high of $110.57, with current price at $100.84 representing an 8.8% decline from the peak. Despite the reduction in share count, Cagnoni maintains substantial holdings of 234,800 shares, indicating continued material ownership stake in the company. Incyte's fundamentals remain solid with annual revenue growth of +21.2%, a net income of $424,169,000, and a P/E of 8.22, providing no obvious deterioration that would explain the sale at this timing relative to recent price momentum.

EVP Issa Mohamed Khairie sold 10,856 shares of INCY at $109.07 for $1,184,063.92; retains 66,132 shares post-transaction.

Issa Mohamed Khairie, EVP Head of US Oncology at Incyte, sold 10,856 shares at $109.07 on 2026-01-07, representing a 14.1% reduction in his holdings from 76,988 to 66,132 shares. The sale occurred at a price just 1.4% below the 52-week high of $110.57, during a period when the stock has posted strong momentum (up 11.3% over 30 days and 26.4% over 90 days). Incyte's fundamentals remain solid with 14.8% annual revenue growth and a P/E of 17.51. The transaction is material in absolute terms ($1.2M) but represents a modest fractional reduction of his stake, leaving him with substantial remaining exposure to the company.

INCY Chief Medical Officer Steven Stein sold 15.6K shares at $101.70, reducing stake to 34.2K shares amid 30.5% 90-day gain.

Steven Stein, EVP & Chief Medical Officer, sold 15,634 shares of Incyte at $101.70 on January 5, 2026, reducing his holdings by 31.4% to 34,203 shares. The transaction occurred while the stock trades near its 52-week high of $110.57, having gained 30.5% over the prior 90 days and 14.3% over the past 30 days. At this same ticker, Stein's prior two sales on December 1-2 saw negative 30-day returns of -4.1% and -3.6% respectively, suggesting recent volatility. His cross-ticker track record shows a 50% well-timed rate on 7 prior sells with modest average returns, though measurable outcomes at Incyte itself are limited for his most recent transactions. The company fundamentals remain solid with $1.4B revenue, $424.2M net income, and 14.8% annual growth, though the 18.28 P/E is elevated given recent price momentum.

INCY EVP Michael James Morrissey sells 58,331 shares for $5.7M via scheduled 10b5-1 plan

Michael James Morrissey, EVP and Head of Technology Operations at Incyte Corp, executed 3 separate sales totaling 58,331 shares for $5,675,001.59 on 2025-12-16 and 2025-12-17 at an average price of $97.29 per share. The sales reduced his holdings from 85,838 shares to 27,507 shares, a reduction of 68.0% of his pre-transaction position. This transaction is part of a pre-arranged 10b5-1 trading plan, indicating the sales were scheduled rather than discretionary. The magnitude of the share reduction and the substantial dollar value warrant attention, though the scheduled nature of the plan removes timing as a signal of his assessment of near-term value.

EVP & CMO Steven H Stein sells 22,664 shares at $102.56 avg for $2.3M, reducing stake by 26.4%

Steven H Stein, Incyte's EVP & Chief Medical Officer, executed two separate sales on consecutive days (December 1–2, 2025) totaling 22,664 shares for $2,324,438.19 at a blended average price of $102.56. This represents a significant 26.4% reduction in his holdings from 85,793 to 63,129 shares. The sales occurred near the 52-week high of $108.26, with the current price at $101.50. Looking at his same-ticker history at INCY, his prior 4 measurable sales showed mixed timing: two generated positive 90-day returns (sales were poorly timed; stock rose after he sold) while two generated negative returns (sales were well-timed). His cross-ticker track record shows a 50% well-timed rate on prior sells with average 90-day returns of +5.1%, indicating his sales do not demonstrate a consistent predictive signal. The company's fundamentals remain solid—$1.4B quarterly revenue with +14.8% annual growth and a P/E of 16.78—providing no obvious distress catalyst. The substantial size and discretionary nature of this sale, combined with the mixed historical timing patterns, warrant attention but do not present an unambiguous signal.

Director Hoppenot Herve sold 187,500 shares of INCY at $105.46, reducing holdings by -36.3% to 329,646 shares; stock at $108.26 current price.

Hoppenot Herve sold 187,500 shares (187.5K shares) at $105.46 on 2025-11-10 for $19,773,750.00 ($19.8M), reducing his position from 517,146 shares to 329,646 shares—a -36.3% reduction in holdings. The sale occurred when INCY stock was trading below its current price of $108.26, near the 52-week high of $108.26, after a 27.8% surge over the prior 30 days and 25.6% gain over 90 days. This substantial reduction in a director's position occurred amid strong recent price momentum and solid fundamentals (Revenue $1.4B, Net income $424.2M, Annual revenue growth +14.8%, P/E 17.89, Market cap $21.3B). The magnitude of the divestiture—representing more than one-third of prior holdings—warrants investor attention alongside the timing relative to recent equity appreciation.